New research suggests that balance and coordination problems in multiple sclerosis may begin when key brain cells slowly run ...

Frustrated by past New Year's resolutions, columnist Desiree Lama is setting intentions to help redefine what progress with ...

Tiziana's foralumab continues to be safe and well-tolerated, with no drug-related serious side effects after long-term use, ...

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

Artificial intelligence (AI), using a simple blood test combined with standard brain images has, for the first time, been ...

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease ...

The 54-year-old star recalled a phase when she had experienced MS flare-up, a moment she described that felt like her own ...

Increasing evidence suggests that the severe gum disease, periodontitis, may contribute to central nervous system disorders ...

MS involves both inflammation and neurodegeneration from the outset, not just one after the other. B-cells, a type of immune cell, are now understood to be critical drivers of the disease, a major ...

Find out how combined chemical exposures and genetics may raise multiple sclerosis risk in new population research.

A new study found smoking cannabis reduced spasticity in MS patients. May 14, 2012— -- Smoking marijuana may reduce certain symptoms in patients with multiple sclerosis, according to a new small ...

Sanofi (SNY) stock is in focus as the company agrees to acquire Dynavax Technologies (DVAX) and the FDA rejects its multiple sclerosis drug tolebrutinib. Read more here.